On 1st August, the online publication of a Meta-analysis Sabatine et al (see pic) from Harvard Medical School let lose another LDL-buster target in their meta-analysis!!! ( Before reading further, please stay focused on the fact that the article is more about LDL-C reduction, not so much about statins alone ) Bottom line message: There is further risk reduction (approximately 20% ) for cardiovascular events by reducing LDL-C from 63 mg/dL to 21 mg/dL with "no observed off-setting adverse effects". This analysis can certainly be revolutionary ... if the results actually get validated ...
I do have my apprehensions too ... read on. Let's take stock from common sense and not statistics. First, THE GOOD : Great statistical science Great trials to seek sampling from Multiple LDL-C lowering therapies included (Statins, Ezetemibe, PCSK9-I Evolocumab, Anacetrapib, Evacetrapib, etc.)…
